中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2015年
25期
56-58,59
,共4页
李艳红%黎艳%李莉%代丹娇
李豔紅%黎豔%李莉%代丹嬌
리염홍%려염%리리%대단교
早期糖尿病肾病%吡格列酮%超敏C反应蛋白%尿白蛋白排泄率
早期糖尿病腎病%吡格列酮%超敏C反應蛋白%尿白蛋白排洩率
조기당뇨병신병%필격렬동%초민C반응단백%뇨백단백배설솔
Early diabetic nephropathy%Pioglitazone%Hypersensitive c-reactive protein%Urinary albumin excretion rate
目的:探讨吡格列酮干预对早期糖尿病肾病患者尿微量白蛋白及hs-CRP等指标的影响,分析其可能的作用机制。方法:选取2013年1月-2014年12月在本院住院治疗的2型糖尿病患者92例,所有患者均为早期糖尿病肾病患者,采用随机数字表法将其分为两组,对照组52例,治疗组40例,对照组保持原有口服降糖药或应用胰岛素降糖治疗,治疗组在原有降糖治疗基础上予以吡格列酮治疗。比较两组处理前后空腹血糖(FBG)、餐后2 h血糖(2 h BG)、空腹胰岛素(FINS)、胰岛素敏感指数(ISI)、总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL-C)、高密度脂蛋白(HDL-C)、糖化血红蛋白(HbA1c)、肝肾功能、24 h尿白蛋白排泄率(UAER)、超敏C反应蛋白(hs-CRP)、胱抑素C(CysC)、同型半胱氨酸(Hcy)等指标的变化。结果:对照组治疗后FBG、2 h BG、LDL-C、HbA1c、hs-CRP均较治疗前降低,比较差异有统计学意义(P<0.05);治疗组治疗后Cr、ALT与治疗前比较差异无统计学意义(P>0.05),其余指标均优于治疗前且优于对照组治疗后,比较差异均有统计学意义(P<0.05)。结论:吡格列酮具有降糖、改善胰岛素抵抗、调脂、增加胰岛素敏感性、降低hs-CRP、减轻炎症反应及减少尿白蛋白排泄的作用。
目的:探討吡格列酮榦預對早期糖尿病腎病患者尿微量白蛋白及hs-CRP等指標的影響,分析其可能的作用機製。方法:選取2013年1月-2014年12月在本院住院治療的2型糖尿病患者92例,所有患者均為早期糖尿病腎病患者,採用隨機數字錶法將其分為兩組,對照組52例,治療組40例,對照組保持原有口服降糖藥或應用胰島素降糖治療,治療組在原有降糖治療基礎上予以吡格列酮治療。比較兩組處理前後空腹血糖(FBG)、餐後2 h血糖(2 h BG)、空腹胰島素(FINS)、胰島素敏感指數(ISI)、總膽固醇(TC)、甘油三酯(TG)、低密度脂蛋白(LDL-C)、高密度脂蛋白(HDL-C)、糖化血紅蛋白(HbA1c)、肝腎功能、24 h尿白蛋白排洩率(UAER)、超敏C反應蛋白(hs-CRP)、胱抑素C(CysC)、同型半胱氨痠(Hcy)等指標的變化。結果:對照組治療後FBG、2 h BG、LDL-C、HbA1c、hs-CRP均較治療前降低,比較差異有統計學意義(P<0.05);治療組治療後Cr、ALT與治療前比較差異無統計學意義(P>0.05),其餘指標均優于治療前且優于對照組治療後,比較差異均有統計學意義(P<0.05)。結論:吡格列酮具有降糖、改善胰島素牴抗、調脂、增加胰島素敏感性、降低hs-CRP、減輕炎癥反應及減少尿白蛋白排洩的作用。
목적:탐토필격렬동간예대조기당뇨병신병환자뇨미량백단백급hs-CRP등지표적영향,분석기가능적작용궤제。방법:선취2013년1월-2014년12월재본원주원치료적2형당뇨병환자92례,소유환자균위조기당뇨병신병환자,채용수궤수자표법장기분위량조,대조조52례,치료조40례,대조조보지원유구복강당약혹응용이도소강당치료,치료조재원유강당치료기출상여이필격렬동치료。비교량조처리전후공복혈당(FBG)、찬후2 h혈당(2 h BG)、공복이도소(FINS)、이도소민감지수(ISI)、총담고순(TC)、감유삼지(TG)、저밀도지단백(LDL-C)、고밀도지단백(HDL-C)、당화혈홍단백(HbA1c)、간신공능、24 h뇨백단백배설솔(UAER)、초민C반응단백(hs-CRP)、광억소C(CysC)、동형반광안산(Hcy)등지표적변화。결과:대조조치료후FBG、2 h BG、LDL-C、HbA1c、hs-CRP균교치료전강저,비교차이유통계학의의(P<0.05);치료조치료후Cr、ALT여치료전비교차이무통계학의의(P>0.05),기여지표균우우치료전차우우대조조치료후,비교차이균유통계학의의(P<0.05)。결론:필격렬동구유강당、개선이도소저항、조지、증가이도소민감성、강저hs-CRP、감경염증반응급감소뇨백단백배설적작용。
Objective:To investigate the influence of Pioglitazone intervention on indexes such as urinary albumin excretion and hypersensitive c-reactive protein in patients with early diabetic nephropathy and its possible mechanism. Method:92 patients with type 2 diabetes hospitalized in our hospital from January 2013 to December 2014 were selected and randomly divided into two groups,with 52 patients in the control group and 40 patients in the treatment group.All patients were with early-stage diabetic nephropathy.The control group was given original oral medicines or insulin for treatment,the treatment group was given Pioglitazone for treatment on the basis of the original glucose-lowering therapy. The indexes such as the fasting blood glucose(FBG),2 hours blood glucose(2 h BG), fasting insulin(FINS), insulin sensitivity index(ISI),glycosylated hemoglobin(HbA1c),total cholesterol(TC),triglycerides(TG),low density lipoprotein cholesterol(LDL-C),high density lipoprotein cholesterol(HDL-C),liver and renal function, 24 hours urinary albumin excretion rate(UAER),hypersensitive c-reactive protein(hs-CRP),cystatin c(CysC) and homocysteine(Hcy) of the two groups were compared before and after treatment.Result:After the treatment,the FBG,2 h BG,LDL-C,HbA1c and hs-CRP of the control group were lower than before treatment,the differences were statistically significant(P<0.05).In the treatment group,the differences in Cr and ALT before and after the treatment were not statistically significant(P>0.05),the other indexes after the treatment were better than before treatment and better than the control group,the differences were statistically significant(P<0.05).Conclusion: Pioglitazone can decrease the level of blood sugar,improve insulin resistance,regulate lipid metabolism,increase the sensitivity of insulin,diminish hs-CRP,reduce inflammatory reaction and urinary albumin excretion.